(Due to the over whelming demand all pharmacy orders are taking up to 2 weeks to arrive.)
Tirzepatide Weight Loss Program
$499.00
A Tirzepatide Injection Once Weekly for the Treatment of Obesity
Tirzepatide – commonly known as Mounjaro™ – is FDA-approved for controlling diabetes similar to Semaglutide (also known as Ozempic®/Wegovy™). During clinical studies it has been shown the efficacy of Tirzepatide for weight loss.
In obesity cases the active ingredient Tirzepatide is being prescribed by doctors off-label for weight loss. Tirzepatide produces weight loss by stimulating two satiety hormone receptors instead of just one with Semaglutide.
Is Tirzepatide an FDA-approved weight loss medication?
Not at this time. Tirzepatide is an FDA-approved injectable medication available by prescription for management of diabetes. Clinical trials and patient experience has shown it’s efficacy as a weight loss treatment. Tirzepatide is being prescribed off-label by doctors for adults who are either overweight or obese.
Is Tirzepatide the same as Mounjaro™ for weight loss?
Yes. Mounjaro® is the brand name medication produced by Eli Lilly that contains Tirzepatide as the active ingredient. Tirzepatide should not be used while taking another GLP-1 receptor such as Ozempic® or Wegovy™. Commonly known as Semaglutide.
How does Tirzepatide work?
Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) receptor . Tirzepatide mimics a hormone called glucagon-like peptide-1 (or GLP-1), which targets areas in the brain that regulate appetite and food intake.
How much weight can I lose with Tirzepatide?
Most patients lose up to 1-2 pounds per week on average with a weekly injection combined with a balanced diet and exercise.
What are the potential side effects of Tirzepatide?
The most common side effects of Tirzepatide are nausea and constipation.
You should avoid taking Tirzepatide if you or your family have a history of medullary thyroid carcinoma (MTC).
How is the Tirzepatide administered?
Tirzepatide is injected by the patient subcutaneously once per week on the same day of the week.